Technical Analysis for BGNE - BeiGene, Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Sell Signal | Bearish | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| NR7 | Range Contraction | -1.18% | |
| NR7-2 | Range Contraction | -1.18% | |
| Gapped Up | Strength | -1.18% | |
| Overbought Stochastic | Strength | -1.18% | |
| Up 3 Days in a Row | Strength | -1.18% | |
| Up 4 Days in a Row | Strength | -1.18% |
| Alert | Time |
|---|---|
| Down 2 % | about 5 hours ago |
| 60 Minute Opening Range Breakdown | about 8 hours ago |
| Down 1% | about 8 hours ago |
| Fell Below Previous Day's Low | about 8 hours ago |
| Up 1% | about 9 hours ago |
Get a Trading Assistant
- Earnings date: 05/02/2024
BeiGene, Ltd. Description
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Monoclonal Antibodies Monoclonal Antibody Lymphoma Oncogenes Protein Kinase Bruton's Tyrosine Kinase Ras Subfamily Rp1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 246.825 |
| 52 Week Low | 126.9681 |
| Average Volume | 211,941 |
| 200-Day Moving Average | 174.96 |
| 50-Day Moving Average | 155.67 |
| 20-Day Moving Average | 146.67 |
| 10-Day Moving Average | 156.06 |
| Average True Range | 5.61 |
| RSI (14) | 60.78 |
| ADX | 23.83 |
| +DI | 34.21 |
| -DI | 22.62 |
| Chandelier Exit (Long, 3 ATRs) | 148.17 |
| Chandelier Exit (Short, 3 ATRs) | 143.80 |
| Upper Bollinger Bands | 169.16 |
| Lower Bollinger Band | 124.19 |
| Percent B (%b) | 0.81 |
| BandWidth | 30.66 |
| MACD Line | 2.68 |
| MACD Signal Line | -0.19 |
| MACD Histogram | 2.8765 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 169.85 | ||||
| Resistance 3 (R3) | 170.09 | 167.25 | 168.30 | ||
| Resistance 2 (R2) | 167.25 | 164.88 | 167.12 | 167.78 | |
| Resistance 1 (R1) | 163.90 | 163.42 | 162.48 | 163.66 | 167.27 |
| Pivot Point | 161.06 | 161.06 | 160.35 | 160.93 | 161.06 |
| Support 1 (S1) | 157.71 | 158.69 | 156.29 | 157.47 | 153.85 |
| Support 2 (S2) | 154.87 | 157.23 | 154.74 | 153.34 | |
| Support 3 (S3) | 151.52 | 154.87 | 152.82 | ||
| Support 4 (S4) | 151.28 |
